natgillin/translations-raw huggingface dataset:
7 hard gastro-resistant capsules 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
7 trdih gastrorezistentnih kapsul 28 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
7 hard gastro-resistant capsules 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
7 trdih gastrorezistentnih kapsul 28 trdih gastrorezstentnih kapsul 98 trdih gastrorezistentnih kapsul
7 hard gastro-resistant capsules, 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules
7 trdih gastrorezistentnih kapsul 28 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul
7 hypodermic injection needle (27 gauge) 14 alcohol swabs.
7 subkutanih injekcijskih igel (27 G) 14 alkoholnih blazinic
7 In active comparator controlled trials oedema was reported in 6.3% of patients treated with metformin and pioglitazone, whereas the addition of sulphonylurea to metformin treatment resulted in oedema in 2.2% of patients.
7 Kontrolirana preskušanja z aktivno primerjavo poročajo o edemih pri 6,3 % bolnikov, zdravljenih z metforminom in pioglitazonom, medtem ko je dodatek sulfonilsečnine metforminu povzročil edeme pri 2,2 % bolnikov.
7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
7 V kliničnih preskušanjih s pioglitazonom je bila incidenca zvišanj ALT na več kot trikratno zgornjo normalno mejo enaka kot pri placebu, a manjša kot v primerjalnih skupinah z metforminom ali sulfonilsečnino.
7 includes fatal cases
Vključujejo smrtne primere.
7 Including fatalities (see section 4.4).
7 Vključno s smrtnimi primeri (glejte poglavje 4.4).
7 injection needle (20 gauge)
7 injekcijskih igel (20 G)
7 inner cartons).
7 notranjih škatel).
7 Mean HbA1c change is the difference between the saxagliptin+metformin and metformin alone groups (p<0.0001).
7 povprečna sprememba HbA1c je razlika med skupinama saksagliptin+metformin in samim metforminom (p<0,0001)
7 mg (21 IU)
7 mg (21 i.e.)
7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.
7 mg na kilogram telesne mase za otroke in mladostnike, ki ne prejemajo rednih transfuzij krvi.
7 mg/kg once every 24 hours
7 mg/kg vsakih 24 ur
7 mg/kg twice daily
7 mg/kg dvakrat na dan
7 Mild hypersensitivity reactions may develop into serious reactions with dyspnoea, fall in blood pressure and sometimes shock.
7 Blage preobčutljivostne reakcije se lahko razvijejo v resne reakcije z dispnejo, padcem krvnega tlaka in včasih šokom.
7 ml clear glass (type I) vial with a green aluminium seal and a green plastic flip-off cap containing 1 ml of concentrate.
ml viala iz prozornega stekla tipa I z zeleno aluminijasto zaporko in zeleno dvižno zaporko z 1 ml koncentrata.
7 ml clear glass (type I) vial with a magenta aluminium seal and a magenta plastic flip-off cap containing 4 ml of concentrate.
ml viala iz prozornega stekla tipa I s škrlatno aluminijasto zaporko in škrlatno dvižno zaporko z 1 ml koncentrata.
7 ml glass vial (freeze- dried component) &
7 ml steklena viala (liofilizirana sestavina) in 105 ml steklenička (tekoča sestavina)
7 ml glass vial (freeze- dried component) &
7 ml steklena viala (liofilizirana sestavina) in 210 ml steklenička (tekoča sestavina)
7 ml/m2/day (8 g/m2/day) in patients with a BSA ≥ 1.3 m2
7 ml/m2/na dan (8 g/m2/na dan) za bolnike s telesno površino ≥ 1,3 m2
7 Not statistically significantly different from placebo.
7 Glede na placebo razlika ni statistično značilna.
7 of 7 subjects with genotype 1b infection and 51 of 56 subjects with genotype 1a infection achieved SVR12.
SVR12 je doseglo 7 od 7 preiskovancev, okuženih z genotipom 1b, in 51 od 56 preiskovancev, okuženih z genotipom 1a.
7 OJ No.
7 OJ št.
7 or 21 hard capsules
7 ali 21 trdih kapsul
7 or 28 tablets in PVC/aluminium foil blister Not all pack sizes may be marketed.
7 ali 28 tablet v pretisnem omotu PVC/aluminijasta folija Na trgu morda ni vseh navedenih pakiranj.
7 patches
7 transdermalnih obližev
7 patients started non-invasive ventilation (BiPAP or CPAP) after baseline (2 patients required brief support with invasive ventilation).
7 bolnikov je začelo neinvazivno ventilacijo (BiPAP ali CPAP) po izhodišču (2 bolnika sta potrebovala kratko invazivno ventilacijsko podporo);
7 patients were weaned off ventilation (time on ventilation from 24 to 168 weeks), all had achieved an RGI-C score ≥2
7 bolnikov je bilo odvajenih od ventilacije (čas na ventilaciji od 24 do 168 tednov), vsi so dosegli oceno RGI-C ≥ 2,
7 pre-filled syringes + 7 alcohol swabs
7 napolnjenih injekcijskih brizg + 7 alkoholnih krpic
7 pre-filled syringes with solvent for parenteral use.
7 napolnjenih injekcijskih brizg z vehiklom za parenteralno uporabo.
7 prolonged-release tablets
7 tablet s podaljšanim sproščanjem
7 prolonged-release tablets of 0.26 mg
7 tablet s podaljšanim sproščanjem po 0,26 mg
7 prolonged-release tablets of 0.52 mg
7 tablet s podaljšanim sproščanjem po 0,52 mg
7 prolonged-release tablets of 1.05 mg
7 tablet s podaljšanim sproščanjem po 1,05 mg
7 sublingual tablets
7 podjezičnih tablet
7 tablets
7 ablet
7 tablets
7 tableti
7 tablets
tablete (PP)
7 tablets (PVC/CTFE/alu blisters) 14 tablets (PVC/CTFE/alu blisters) 28 tablets (PVC/CTFE/alu blisters) 49 tablets (PVC/CTFE/alu blisters) 56 tablets (PVC/CTFE/alu blisters) 98 tablets (PVC/CTFE/alu blisters) 7 tablets (PVC/PVDC/alu blisters) 14 tablets (PVC/PVDC/alu blisters) 28 tablets (PVC/PVDC/alu blisters) 49 tablets (PVC/PVDC/alu blisters) 56 tablets (PVC/PVDC/alu blisters) 98 tablets (PVC/PVDC/alu blisters)
7 tablet (PVC/CTFE/ALU pretisni omoti) 14 tablet (PVC/CTFE/ALU pretisni omoti) 28 tablet (PVC/CTFE/ALU pretisni omoti) 49 tablet (PVC/CTFE/ALU pretisni omoti) 56 tablet (PVC/CTFE/ALU pretisni omoti) 98 tablet (PVC/CTFE/ALU pretisni omoti) 7 tablet (PVC/PVDC/ALU pretisni omoti) 14 tablet (PVC/PVDC/ALU pretisni omoti) 28 tablet (PVC/PVDC/ALU pretisni omoti) 49 tablet (PVC/PVDC/ALU pretisni omoti) 56 tablet (PVC/PVDC/ALU pretisni omoti) 98 tablet (PVC/PVDC/ALU pretisni omoti)
7 tablets 10 tablets
7 tablet 10 tablet
7 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
7 tablet v pretisnih omotih iz papirja/aluminija/najlona/aluminija/PVC.
7 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
tablet v pretisnih omotih iz papirja/aluminija/najlona/aluminija/PVC.
7 tablets.
7 tablet.
7 to 11 years
7 do 11 let
7 to 14 mg/kg once
7 do 14 mg/kg enkrat na
7 to less than 13
7 do manj kot 13
7 transdermal patches
7 transdermalnih obližev
7 transdermal patches of Leganto 4 mg/24 h 7 transdermal patches of Leganto 6 mg/24 h 7 transdermal patches of Leganto 8 mg/24 h
7 transdermalnih obližev Leganto 4 mg/24 h 7 transdermalnih obližev Leganto 6 mg/24 h 7 transdermalnih obližev Leganto 8 mg/24 h
7 transdermal patches of Neupro 4 mg/24 h 7 transdermal patches of Neupro 6 mg/24 h 7 transdermal patches of Neupro 8 mg/24 h
7 transdermalnih obližev Neupro 4 mg/24 h 7 transdermalnih obližev Neupro 6 mg/24 h 7 transdermalnih obližev Neupro 8 mg/24 h
7 transdermal patches.
7 transdermalnih obližev
7 vials + 7 sterile syringes + 14 alcohol swabs
7 vial + 7 sterilnih brizg + 14 alkoholnih zložencev
7 vials with 7 sterile 1 mL injection syringes with retractable injection needle and 14 alcohol swabs.
7 vial s 7 sterilnimi 1-mililitrskimi injekcijskimi brizgami z vskočno injekcijsko iglo in 14 alkoholnimi zloženci.
7 vials with powder for solution for injection.
7 vial s praškom za raztopino za injiciranje.
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● Združeno kraljestvo
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
7 Westferry Circus, Canary Wharf, London E14 4HB, UK (44-20) 74 18 84 00 Faks (44-20) 74 18 84 16
7 x 1 capsules (unit dose)
7 x 1 kapsula (enkratni
7 x 1 film-coated tablets
7 x 1 filmsko obložena tableta
7 x 1 tablets (unit
7 x 1 tableta (enoodmerni pretisni)
7 x 20 mg + 7 x 80 mg capsules
7 x 20 mg + 7 x 80 mg kapsul
7 x 20 mg and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply)
7 x 20 mg in 7 x 80 mg kapsule (odmerek 100 mg/dan, zaloga za 7 dni)
7 x 8.4 g syringes
7 x 8,4 g brizg
7 years
let
7 yrs
7 let
7% had an unknown metastatic status
7 % neznano stanje glede metastaz,
7, 14, 28, 30, 50, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters
7, 14, 28, 30, 50, 84, 90 in 100 tablet v PVC/PVDC/alu pretisnih omotih ali v pretisnih omotih iz aluminija,
7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters
7, 14, 28, 30, 84, 90 in 100 tablet v PVC/PVDC/alu pretisnih omotih ali v pretisnih omotih iz aluminija,
7, 28 and 98 capsules
7, 28 in 98 kapsul
7, rue du Fer à Moulin – BP 09 F-75221 Paris Cedex 05 FRANCE
7, rue du Fer à Moulin – BP 09 F-75221 Pariz Cedex 05 FRANCIJA
7,000 IU/0.7 ml
7.000 i.e./0,7 ml
7,500 U/m²; > 12 months: 10,000 U/m²) on days 15, 18, 22, 25, 29, and 33 of induction treatment.
6 - 12 mesecev: 7.500 E/m²; >12 mesecev: 10.000 E/m²) na 15., 18., 22., 25., 29. in 33. dan indukcijskega zdravljenja.
7-valent Prevenar), as recommended by the WHO.
7-valentno cepivo Prevenar).
7-Year EFS Rate, % (95% CI)
7-letni delež EFS, % (95-odstotni IZ)
7.) If the average radiochemical purity is less than 95%, the preparation must not be administered.
Če znaša povprečna radiokemijska čistota manj kot 95 %, se preparat ne sme aplicirati.
7.0 m vs 4.1 m p=0.0012 HR 1.24 [0.94, 1.64]
7,0 m v prim. s 4,1 m
7.1%
°C)
7.1% (-47.1% to 61.4%)
7,1 % (–47,1 % do 61,4 %)
7.1-8.0 mmol/l (127-144 mg/dl)
7,1-8,0 mmol/l (127–144 mg/dl)
7.17 µg/ml).
7,17 µg/ml).
7.2 %) which, however normalises spontaneously.
7,2 %), ki pa se normalizira sama od sebe.
7.2 (5.9, NR)
7,2 (5,9, ND)
7.2 mg/mL.
7,2 mg/ml.
7.3.1 Preparing for the injection
Priprava na injiciranje
7.32 g of oral paste
7.32 g peroralne paste.
7.35 mg sodium per ml reconstituted solution (18.4 mg sodium per vial).
7,35 mg natrija na ml rekonstituirane raztopine (18,4 mg natrija na vialo).
7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p = 0.017
12,7 dogodka/1.000 bolnikov-let, p = 0,017;
7.5 hours from the time of calibration
7,5 ur od časa kalibracije.
7.5 mg fondaparinux sodium in 0.6 ml solution for injection
7,5 mg natrijevega fondaparinuksa v 0,6 ml raztopine za injiciranje.
7.5 mg fondaparinux sodium in 0.6 ml solution for injection
7,5 mg natrijevega fondaparinuksata v 0,6 ml raztopine za injiciranje.
7.5 mg morphine in patients treated with IONSYS compared to a mean dose of 5.4 – 7.7mg morphine in patients receiving PCA morphine. .
V 4 študijah je bil povprečni odmerek morfina 5,0 – 7,5 mg pri bolnikih, ki so se zdravili z zdravilom IONSYS, v primerjavi s povprečnim odmerkom 5,4 – 7,7 mg morfina pri bolnikih, ki so uporabljali črpalko PCA.
7.5 mg once a day
7,5 mg enkrat na dan
7.5 mg once daily2
5 mg enkrat na dan.
7.5 mg once daily2
7,5 mg enkrat na dan2 15 mg vsak drugi dan
7.5 mg/kg every 24 hours
7,5 mg/kg vsakih 24 ur
7.5 mg/kg intravenous 30-90 mins
7,5 mg/kg intravensko 30–90 min
7.5 micrograms/
7,5 mikrogram
7.5 ml once daily
7.5 ml enkrat na dan
7.5 ml twice daily
7.5 ml dvakrat na dan
7.5.1 Symbols printed on the administration system
Simboli, prikazani na aplikacijskem sistemu
7.6 (2.1-18.0), and 4.0 (1.5-6.6) μg/ml, respectively.
4,0 μg/ml (1,5-6,6).
7.6 (5.9, NR)
7,6 (5,9, ND)
7.6 Technical characteristics
Tehnične značilnosti
7.61B [5.17; 11.21]
1,35 (17,1 %)
7.67 mg methyl parahydroxybenzoate (E218)
7,67 mg metilparahidroksibenzoata (E218) 0,85 mg propilparahidroksibenzoata (E216)
7.7 hours in young cattle.
max µg/ml po 7,7 ure.
7.7 mg pyriproxifen, 635 mg permethrin
7.7 mg piriproksifen, 635 mg permetrin
7.8. Further dilution is required.
Raztopino moramo še nadalje redčiti.
7.94mm round, green tablets debossed with ‘3MG’ on one side and ‘503’ on the other side.
Okrogle, zelene tablete, 7,94 mm v premeru, z vtisnjenim napisom ‘3MG’ na eni strani in ‘503’ na drugi strani.
70 (2 x 35)
70 (2 x 35) tablet
70 (2 x 35) tablets
(večkratno pakiranje) 70 (2 x 35) tablet
70 (2 x 35) tablets
70 (2 x 35) tablet
70 capsules
70 kapsul
70 coated tablets
70 obloženih tablet
70 doctor if they do not disappear after a few weeks.
Če ne minejo po nekaj tednih, pojdite k zdravniku.
70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week).
5 dni na teden v celotnem odmerku 66 do 70 Gy), ali s pospešenimi/ hiperfrakcioniranimi shemami obsevalnega zdravljenja (dvakrat na dan, z minimalnim intervalom med frakcijama 6 ur, 5 dni na teden).
70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week).
5 dni na teden v celotnem odmerku 66 do 70 Gy), ali s pospešenimi/hiperfrakcioniranimi shemami obsevalnega zdravljenja (dvakrat na dan, z minimalnim intervalom med frakcijama 6 ur, 5 dni na teden).
70 hard capsules
70 trdih kapsul
70 mg (from two 50 mg vials)**
70 mg (iz dveh vial po 50 mg)
70 mg (from two 50-mg vials)**
70 mg (iz dveh vial po 50 mg)
70 mg/2800 IU
70 mg/2800 i.e.
70 mg/5,600 IU after an overnight fast and two hours before a meal, the mean area under the serum- concentration-time curve (AUC0-80 hrs) for vitamin D3 (unadjusted for endogenous vitamin D3 levels) was 490.2 nghr/ml.
70 mg/5.600 i.e. zjutraj na tešče in dve uri pred obrokom povprečna površina pod krivuljo serumska koncentracija-čas (AUC0-80 ur) za vitamin D3 (neprilagojen endogenim vrednostim vitamina D3) znašala 490,2 ngh/ml.
70 mg/5,600 IU tablets are available in packs containing 2, 4 or 12 tablets.
70 mg/5.600 i.e tablete so na voljo v pakiranjih, ki vsebujejo 2, 4 ali 12 tablet.
70 mg/5600 IU
70 mg/5600 i.e.
70 subjects (Child- Pugh Class A, n=64; Child-Pugh Class B, n=6) were randomized to the maraviroc group and 67 subjects (Child-Pugh Class A, n=59; Child-Pugh Class B, n=8) were randomized to the placebo group.
B. 70 preiskovancev (Child-Pugh A, N = 64; Child-Pugh B, N = 6) so randomizirali v skupino z maravirokom, 67 preiskovancev (Child-Pugh A N = 59, Child-Pugh B N = 8) pa v skupino s placebom.
70 subjects (Child- Pugh Class A, n=64; Child-Pugh Class B, n=6) were randomized to the maraviroc group and 67 subjects (Child-Pugh Class A, n=59; Child-Pugh Class B, n=8) were randomized to the placebo group.
B. 70 preiskovancev (Child-Pugh A, N = 64; Child-Pugh B, N = 6) so randomizirali v skupino z maravirokom, 67 preiskovancev (Child-Pugh A, N = 59; Child-Pugh B, N = 8) pa v skupino s placebom.
70 tablets
35 tablet
70 tablets
tablete (PP)
70 x (90-15) x 0.5 = 2,625 IU.
70 x (90 – 15) x 0,5 = 2,625 i.e.
70 x 1 film-coated tablets
70 x 1 filmsko obložena tableta
70 x 1, 98 or 98 x 1 film-coated tablets per carton.
56, 56 x 1, 70, 70 x 1, 98 ali 98 x 1 filmsko obložena tableta.
70% soluble insulin aspart and 30% insulin aspart crystallised with protamine
70 % topnega insulina aspart in 30 % s protaminom kristaliziranega insulina aspart
70%, and preferably also include PFS2, or, at least, time on next therapy.
Vključujejo naj PFS2 ali vsaj čas do naslednje terapije.
70, avenue du Général de Gaulle F-92800 Puteaux
70, avenue du Général de Gaulle F-92800Puteaux
70.6 (49.0-NA)
0,70 (0,54–0,90)
70.6 (49.0-NA)
70,6 (49,0–NP)
70.7 weeks) for patients receiving selexipag versus 71.2 weeks (median 63.7 weeks) for patients on placebo.
76,4 tednov (mediana 70,7 tednov) za bolnike, ki so prejemali seleksipag, v primerjavi z 71,2 tedni (mediana 63,7 tednov) za bolnike na placebu.
70.8%
6–35 mesecev
70.9 or greater
70,9 ali več
700
DOE
700 mg (1 tablet or 14 ml suspension)
700 mg (1 tableta ali 14 ml suspenzije)
700/100 mg twice daily
700/100 mg dvakrat na
7000 microgram (mcg/ml) for patients >2 years of age with a BSA of ≤1.3
7000 mikrogramov (μg/ml) za bolnike starosti >2 let s telesno površino ≤1,3
71-80 years
>80 let
71.2% vs 47.3%
71,2 % v prim. s
72 hours*
72 ur
72 hours; vardenafil should be used
vardenafil je treba uporabljati
72 IU/kg)
72 a.e./kg)
72 ml/hr is reached.
72 ml/uro.
72 or 48 Weeks
72 ali 48 tednov
72 spot-on applicators
72 aplikatorjev za kožni nanos
72 Weeks
72 tednov
72% of patients were never smokers, 99% of patients had a World Health Organization (WHO) performance status of 0 or 1 and 39% of patients had brain metastases (stable for at least 4 weeks and not requiring corticosteroids).
72 % bolnikov ni nikoli kadilo, 99 % bolnikov je imelo stanje zmogljivosti 0 ali 1 po Svetovni zdravstveni organizaciji (WHO – World Health Organization) in 39 % bolnikov je imelo metastaze v možganih (stabilne vsaj 4 tedne in brez potrebe po kortikosteroidih).
72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week.
Pri 72,2 % bolnikov, ki so se zdravili z levetiracetamom, in 45, 2 % bolnikov, ki so prejemali placebo, je bilo 50 ali več odstotno zmanjšanje pogostnosti PGTC napadov na teden.
72.7 (61.3 to
72,7 (61,3-83,0)
7255 LX Hengelo (Gld) THE NETHERLANDS.
7255 LX Hengelo (Gld) NIZOZEMSKA
726 IU/g
726 i.e./g
726/2004, the MAH shall complete, within the stated timeframe, the following measures:
726/2004, mora imetnik dovoljenja za promet z zdravilom v določenem časovnem okvirju izvesti naslednje ukrepe:
73 %
Parameter
73 infants 6-11 months old and 73 toddlers 12-35 months old, receiving the 7.5 µg formulation were reported as follows:
11 mesecev, in 73 malčkih, starih 12–35 mesecev, ki so prejeli formulacijo 7,5 µg, so bili, kot sledi:
73% of the cutaneous reactions were reversible within 21 days.
Pojavljale so se reverzibilne, praviloma blage do zmerne kožne reakcije.
73% – 95% of the daily dose of total radioactivity was recovered from the faeces.
V iztrebkih je bilo zaznanih 73 % - 95 % dnevnega odmerka skupne radioaktivnosti.
73, rue de Stalle B-1180 Bruxelles Belgium
73, rue de Stalle B-1180 Bruxelles Belgija
73.8% (59/80) of patients in the pooled peginterferon alfa-2a group met the criteria (undetectable HCV RNA (target not detected) at week 4 through week 20) for the shortened 24 week peginterferon/ribavirin treatment duration versus 61.7% (50/81) of patients in the pooled peginterferon alfa-2b group.
V združeni skupini, ki je prejemala peginterferon alfa-2a je 73,8% (59/80) bolnikov v primerjavi z 61,7% (50/81) v združeni skupini, ki je prejemala peginterferon alfa-2b, doseglo kriterije za skrajšanje zdravljenja s peginterferonom/ribavirinom na 24 tednov (nezaznavna koncentracija HCV RNK (nezaznaven analit) med tedni 4 do 20).
73614 Schorndorf Germany
D-73614 Schorndorf Nemčija
74540 Alby-sur-Chéran France
74540 Alby-sur-Chéran Francija
747 70 Opava Komárov Czech Republic
747 70 Opava Komárov Češka
747 70 Opava Komárov Czech Republic
747 70 Opava Komárov Češka republika
747 70 Opava-Komarov Czech Republic
747 70 Opava-Komarov Češka
75 % of previous dose
75% predhodnega odmerka
75 % of previous dose (both ALIMTA and cisplatin )
75 % predhodnega odmerka (obeh ALIMTE in cisplatina)
75 % of previous dose (both CIAMBRA and cisplatin)
75 % predhodnega odmerka (obeh, zdravila CIAMBRA in cisplatina)
75 % of previous dose (both Pemetrexed Lilly and cisplatin )
75 % predhodnega odmerka (obeh Pemetreksed Lilly in cisplatina)
75 % of previous dose (both Pemetrexed Lilly and cisplatin)
75 % predhodnega odmerka (obeh Pemetreksed Lilly in cisplatina)
75 (21.4)
placebo/deks (n=351)
75 IU
ime
75 IU (150 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
75 i.e. (150 i.e./ml) aktivnosti rekombinantnega folikle stimulirajočega hormona (FSH).
75 IU (5.5 μg)
75 i.e. (5,5 μg)
75 IU r-hLH
75 i.e. r-hLH
75 IU/0.125 ml
75 i.e./0,125 ml
75 IU/0.5 mL
75 i.e./0,5 ml
75 kg patient is initiated at 1 µg/kg of romiplostim.
Zdravljenje 75 kg bolnika se začne z 1 µg/kg romiplostima.
75 mg 13C-
75 mg 13C sečnine
75 mg can be made up of a 30 mg capsule plus a 45 mg capsule
75 mg lahko pripravite iz 30 mg kapsule in 45 mg kapsule
75 mg can be made up of a 30 mg capsule plus a 45 mg capsule
75 mg lahko pripravite iz 30-mg kapsule in 45-mg kapsule
75 mg doses can be administered as either
75-mg odmerek lahko damo kot:
75 mg doses can be administered as either
75-mg odmerek lahko damo:
75 mg doses can be administered as either:
75 mg odmerek lahko damo kot:
75 mg film-coated tablets Clopidogrel
75 mg filmsko obložene tablete klopidogrel
75 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).
75 mg filmsko obložene tablete: polivinilalkohol, titanov dioksid (E171), makrogol 3350, smukec, rumeni železov oksid (E172), rdeči železov oksid (E172), črni železov oksid (E172).
75 mg is made up of a 30 mg dose plus a 45 mg dose
75 mg lahko pripravite iz 30-mg odmerka in 45-mg odmerka
75 mg of ibafloxacin per ml of gel
75 mg ibafloksacina v 1 ml gela
75 mg once daily
75 mg dvakrat na dan
75 mg oseltamivir suspension delivers 2.1 g of sorbitol.
75 mg suspenzije oseltamivir vsebuje 2,1 g sorbitola.
75 mg suspension for injection
75 mg suspenzija za injiciranje
75 mg), palonosetron 20 mcg/kg (maximum 1.5 mg) or ondansetron (3 x 0.15 mg/kg , maximum total dose 32 mg) 30 minutes prior to the start of emetogenic chemotherapy during Cycle 1.
10 mcg/kg (največji odmerek 0,75 mg), palonosetronom 20 mcg/kg (največji odmerek 1,5 mg) ali ondansetronom (3 x 0,15 mg/kg , največji celotni odmerek 32 mg) 30 minut pred začetkom emetogene kemoterapije med ciklom 1.
75 mg/kg feed) for 10 days improved the clinical condition of the pigs, reduced diarrhoea and improved productivity.
75 mg/kg krme) v 10 dneh izboljšalo klinično stanje prašičev, zmanjšalo drisko in izboljšalo produktivnost.
75 mg/kg feed) for at least 7 days successfully treated swine dysentery.
75 mg/kg krme) vsaj 7 dni.
75 mg/ml solution for injection
Raztopina za injiciranje 75 mg/ml
75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 4.
75 mg/m2, temu pa 5-fluorouracil (F) 750 mg/m2 na dan v obliki neprekinjene infuzije 5 dni.
75 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 75 mikrogramov
75 to 60 mg/m².
75 na 60 mg/m2.
75 years did not identify age as significantly influencing entecavir pharmacokinetics.
Analiza populacijske farmakokinetike pri bolnikih, starih od 16 do 75 let, ne kaže, da bi starost pomembneje vplivala na farmakokinetiko entekavirja.
75 years; DFSP was metastatic, locally recurrent following initial resective surgery and not considered amenable to further resective surgery at the time of study entry.
DFSP je bil metastatičen, z lokalno ponovitvijo po začetni kirurški odstranitvi in v času vključitve v študijo ocenjen kot neprimeren za nadaljnje kirurško odstranjevanje.
75 yrs
75 let
75% dose reduction
75 % zmanjšanje odmerka
75% of previous dose (both Pemetrexed Hospira and cisplatin)
75 % predhodnega odmerka (obeh - zdravila Pemetreksed Hospira in cisplatina)
75% of previous dose (both Pemetrexed Hospira and cisplatin)
75 % predhodnega odmerka (obeh -zdravila Pemetreksed Hospira in cisplatina)
75% of the dose recovered within 96 hours.
75 % odmerka se je izločilo v 96 urah.
75) at week 13
13. tednu
75.6 micrograms
75,6 mikrogramov
750 IU/ml after reconstitution)
750 i.e./ml po rekonstituciji).
750 mg every 8 hours
750 mg na 8 ur
750 mg q8h)
na 8 h)
750 mg tablet: glycerol triacetate, lactose monohydrate, Blue #1/Brilliant Blue FCF Aluminium Lake (E133) and Yellow #5/Tartrazine Aluminium Lake (E102)
750-miligramska tableta: gliceroltriacetat, laktozo monohidrat, modro aluminijevo barvilo FCF št.1 (E133) in rumeno aluminijevo barvilo tartrazin št.
750 mg tablet: indigo carmine aluminium lake (E132), sunset yellow FCF aluminium lake (E110) 1000 mg tablet: (no additional colourant).
750 mg tableta: indigotin (E132), sončno rumeno FCF (E110) 1000 mg tableta: (ni dodatnega barvila)
750 mg tablet: sunset yellow FCF (E110), iron oxide red (E172)
750 mg tableta: sončno rumeno FCF (E110), rdeči železov oksid (E172)